VEGF-C Antibody [Alexa Fluor® 594]

• Applications: WB, ELISA, IHC
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Alexa Fluor 594

VEGF-C Antibody [Alexa Fluor® 594] Summary

• Immunogen: E. coli-derived recombinant human VEGF-C
• Specificity: Detects human VEGF-C in direct ELISAs and Western blots.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Purity Statement: Antigen Affinity-purified

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Background

Vascular endothelial growth factor C (VEGF-C) and VEGF-D constitute a VEGF sub-family that share the conserved VEGF homology domain (VHD) with other VEGF family members but are distinguished by their preferential formation of non-covalent homodimers. Both VEGF-C and -D have long N- and C-terminal propeptide extensions. The VEGF-C propeptide undergoes stepwise proteolytic processing to generate ligands with increasing affinity for VEGF-R3. However, only the fully processed VEGF-C containing just the VHD can bind VEGF-R2. None of the VEGF-C forms have appreciable affinity for VEGF-R1. VEGF-C is expressed in multiple adult human tissues, most prominently in lymph nodes, heart, placenta, ovary, and small intestine. Traces of VEGF-C are also detected in brain, liver, thymus, skeletal muscles, spleen, prostate, testis and colon. Unlike other VEGF family members, VEGF-C expression is not regulated by hypoxia. VEGF-C is a lymphangiogenic growth factor and the VEGF-C/VEGF-R3 signaling pathway has been shown to be crucial for lymphangiogenesis. VEGF-C and VEGF-R3 are usually co-expressed at sites with lymphatic vessel sprouting, in the embryo, and in various pathological conditions. VEGF-C stimulates lymphangiogenesis in the avian chorioallantoic membrane model. Over-expression of VEGF-C in breast cancer cells has been shown to increase intratumoral lymphangiogenesis, resulting in enhanced metastasis to regional lymph nodes and to the lungs. Mouse tumors expressing elevated levels of VEGF-C have increased lymphatic metastasis and increased lymphatic surface area in the tumor margin. VEGF-C is also associated with lymph node metastasis of colorectal carcinoma. Besides lymphangiogenesis, VEGF-C can have potent effects on physiological angiogenesis through its interaction with VEGF R2. The protein can stimulate migration and proliferation of endothelial cells in vitro and in vivo and has been shown to stimulate angiogenesis in the mouse cornea and in rabbit hind limb ischaemia.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

FAQs for VEGF-C Antibody (AF752T). (Showing 1 - 1 of 1 FAQ).

1. I was wondering if you know of any blocking antibodies against IL-6 or VEGF-C that can be used in cell culture to quench these cytokines?
   • We have no antibodies that are currently known to show blocking antibodies to VEGF-C. Please see this link to our IL-6 antibodies with blocking/neutralizing activity can be found at this link.